Based on the Recursion Pharmaceuticals Inc stock forecast from 3 analysts, the average analyst target price for Recursion Pharmaceuticals Inc is USD 9.50 over the next 12 months. Recursion Pharmaceuticals Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Recursion Pharmaceuticals Inc is Slightly Bearish, which is based on 4 positive signals and 6 negative signals. At the last closing, Recursion Pharmaceuticals Inc’s stock price was USD 4.24. Recursion Pharmaceuticals Inc’s stock price has changed by -27.02% over the past week, -35.56% over the past month and -52.20% over the last year.
No recent analyst target price found for Recursion Pharmaceuticals Inc
No recent average analyst rating found for Recursion Pharmaceuticals Inc
Company Overview Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah. Read Less
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops ...Read More
Frequently Asked Questions About Recursion Pharmaceuticals Inc (RXRX) Stock
Based on ratings from 3 analysts Recursion Pharmaceuticals Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 3 buy, sell and 1 hold ratings.
Unfortunately we do not have enough data on RXRX's stock to indicate if its a good dividend stock.
Based on targets from 3 analysts, the average taret price for RXRX is USD 9.50 over the next 12 months. The maximum analyst target price is USD 11 while the minimum anlayst target price is USD 6.
Unfortunately we do not have enough data on RXRX's stock to indicate if its overvalued.
The last closing price of RXRX's stock was USD 4.24.
The most recent market capitalization for RXRX is USD 2.44B.
Based on targets from 3 analysts, the average taret price for RXRX is projected at USD 9.50 over the next 12 months.
This means that RXRX's stock price may go up by +124.06% over the next 12 months.
We can't find any ETFs which contains Recursion Pharmaceuticals Inc's stock.
As per our most recent records Recursion Pharmaceuticals Inc has 800 Employees.
Recursion Pharmaceuticals Inc's registered address is 41 South Rio Grande Street, Salt Lake City, UT, United States, 84101.
You can get more information about it from Recursion Pharmaceuticals Inc's website at https://www.recursion.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low debt
The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Recursion Pharmaceuticals Inc (RXRX) Stock
Based on ratings from 3 analysts Recursion Pharmaceuticals Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 3 buy, sell and 1 hold ratings.
Unfortunately we do not have enough data on RXRX's stock to indicate if its a good dividend stock.
Based on targets from 3 analysts, the average taret price for RXRX is USD 9.50 over the next 12 months. The maximum analyst target price is USD 11 while the minimum anlayst target price is USD 6.
Unfortunately we do not have enough data on RXRX's stock to indicate if its overvalued.
The last closing price of RXRX's stock was USD 4.24.
The most recent market capitalization for RXRX is USD 2.44B.
Based on targets from 3 analysts, the average taret price for RXRX is projected at USD 9.50 over the next 12 months.
This means that RXRX's stock price may go up by +124.06% over the next 12 months.
We can't find any ETFs which contains Recursion Pharmaceuticals Inc's stock.
As per our most recent records Recursion Pharmaceuticals Inc has 800 Employees.
Recursion Pharmaceuticals Inc's registered address is 41 South Rio Grande Street, Salt Lake City, UT, United States, 84101.
You can get more information about it from Recursion Pharmaceuticals Inc's website at https://www.recursion.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for RXRX !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
